[New aspects of tuberculosis therapy].
The introduction of ethambutol and rifampicin has modified the therapy of tuberculosis. Therapy in hospitals or sanatoria can be shortened, and intermittent regimens (once or twice weekly under supervision) are possible. Better knowledge of the side effects of particular drugs, particularly rifampicin, (such as allergic reactions in intermittent administration and reduced effect of oral contraceptives) has been gained. Instead of mere supervision, preventive chemotherapy is given in many cases such as in recently discovered fibrotic lesions and in high risk cases (silicosis, treatment with corticosteroids and immunosuppressive agents)minadequate treatment may lead to functional impairment such as fibrosis and cor pulmonale. These aspects are discussed and the resultant guidelines for the treatment of tuberculosis are presented.
D003276:Contraceptives, Oral / Q000037:antagonists & inhibitors; D004977:Ethambutol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008598:Menstruation / Q000187:drug effects; D008722:Methods; D011660:Pulmonary Heart Disease / Q000139:chemically induced; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013307:Streptomycin / Q000627:therapeutic use; D013997:Time Factors; D014376:Tuberculosis / Q000188:drug therapy*
D003276:Contraceptives, Oral; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin
Neuere Gesichtspunkte zur Tuberkulosetherapie